| Line Item | 2024-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1K | -43.0% | -68.5% |
| SG&A Expense | $52K | +12.0% | -34.7% |
| Net Income | -$69K | +13.5% | +50.8% |
| EPS (Basic) | $0.00 | — | — |
| Line Item | 2024-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $15K | -48.7% | -93.6% |
| Total Assets | $25K | -43.8% | -89.8% |
| Current Liabilities | $692K | +137.0% | +173.3% |
| Stockholders' Equity | -$317K | -28.1% | -5002.9% |
| Line Item | 2024-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$152K | — | — |